Sarepta Therapeutics (NASDAQ:SRPT) Earns Sell Rating from HC Wainwright

HC Wainwright restated their sell rating on shares of Sarepta Therapeutics (NASDAQ:SRPT - Free Report) in a research note issued to investors on Wednesday morning,Benzinga reports. The firm currently has a $75.00 price objective on the biotechnology company's stock.

SRPT has been the topic of several other reports. StockNews.com cut shares of Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday, November 20th. Scotiabank started coverage on shares of Sarepta Therapeutics in a research report on Friday, March 7th. They set a "sector perform" rating and a $105.00 price objective on the stock. Royal Bank of Canada lowered their price objective on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an "outperform" rating on the stock in a research report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft started coverage on shares of Sarepta Therapeutics in a research report on Tuesday, February 11th. They set a "hold" rating and a $136.00 price objective on the stock. Finally, Needham & Company LLC restated a "buy" rating and set a $202.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $167.41.

Remove Ads

Sarepta Therapeutics Price Performance

NASDAQ SRPT traded up $0.65 on Wednesday, hitting $74.10. The stock had a trading volume of 2,591,321 shares, compared to its average volume of 1,218,291. Sarepta Therapeutics has a 52-week low of $73.05 and a 52-week high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The company has a market capitalization of $7.19 billion, a price-to-earnings ratio of 59.28 and a beta of 0.79. The firm has a 50-day moving average of $107.19 and a 200-day moving average of $117.88.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the firm's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the sale, the director now owns 27,812 shares of the company's stock, valued at $2,771,187.68. This trade represents a 8.22 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 7.70% of the company's stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Large investors have recently added to or reduced their stakes in the company. Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Sarepta Therapeutics by 21.4% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,700 shares of the biotechnology company's stock worth $212,000 after purchasing an additional 300 shares during the period. Oppenheimer Asset Management Inc. lifted its position in shares of Sarepta Therapeutics by 3.4% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company's stock worth $557,000 after purchasing an additional 145 shares during the period. Huntington National Bank lifted its position in shares of Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 175 shares during the period. CIBC Asset Management Inc lifted its position in shares of Sarepta Therapeutics by 3.3% in the 3rd quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company's stock worth $339,000 after purchasing an additional 86 shares during the period. Finally, Commerce Bank lifted its position in shares of Sarepta Therapeutics by 15.7% in the 3rd quarter. Commerce Bank now owns 2,016 shares of the biotechnology company's stock worth $252,000 after purchasing an additional 274 shares during the period. Institutional investors own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.